Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

References

• Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605. doi:10.1016/j.clindermatol.2018.05.007
   PubMed Web of Science ®Google Scholar
• Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(4):360–366. doi:10.1016/j.anai.2018.12.017
   PubMed Web of Science ®Google Scholar
• Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi:10.3390/ijms22084130
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi:10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi:10.1016/S0140-6736(21)00588-2
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi:10.1016/S0140-6736(20)30732-7
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343. doi:10.1001/jamadermatol.2020.3260
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047–1055. doi:10.1001/jamadermatol.2021.3023
   PubMed Web of Science ®Google Scholar
• Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112. doi:10.1056/NEJMoa2019380
   PubMed Web of Science ®Google Scholar
• Simpson EL, Silverberg JI, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. Am J Clin Dermatol. 2023;24(4):609–621. doi:10.1007/s40257-023-00785-5
   PubMed Web of Science ®Google Scholar
• Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37:2537–2542. doi:10.1111/jdv.19378
   PubMed Web of Science ®Google Scholar
• Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543–e546. doi:10.1111/jdv.18804
   PubMed Web of Science ®Google Scholar
• De Greef A, Thirion R, Ghislain PD, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther. 2023;13(11):2869–2877. doi:10.1007/s13555-023-01030-x
   Google Scholar
• Gargiulo L, Ibba L, Vignoli CA, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J DermatolTreat. 2023;34(1):2268764. doi:10.1080/09546634.2023.2268764
   Google Scholar
• Reguiai Z, Becherel PA, Fougerousse AC, et al. Janus kinase inhibitors for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the pharmacovigilance risk assessment committee recommended measures. J Eur Acad Dermatol Venereol. 2023;37(11):e1307–e1309. doi:10.1111/jdv.19302
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Rinvoq (upadacitinib): summary of product characteristics; 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq. Accessed February 27, 2024.
   Google Scholar
• European Medicines Agency. Cibinqo (abrocitinib): summary of product characteristics. 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo. Accessed February 27, 2024.
   Google Scholar
• European Medicines Agency. Olumiant (baricitinib): summary of product characteristics. 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant. Accessed February 27, 2024.
   Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi:10.1016/S0140-6736(21)00589-4
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123–e130. doi:10.1136/bmj.327.7423.1083
   PubMedGoogle Scholar
• Melgosa Ramos FJ, González-Delgado V, Motilla JMS, Marta GP, Mateu Puchades A, Sergio SA. Upadacitinib effectiveness in moderate-to-severe atopic dermatitis: a real-life multicentre and retrospective study. Australas J Dermatol. 2023;64(4):e361–e364. doi:10.1111/ajd.14164
   PubMed Web of Science ®Google Scholar
• De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Adv Ther. 2023;40(5):2509–2514. doi:10.1007/s12325-023-02490-5
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24:953–961. doi:10.1007/s40257-023-00798-0
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Piscazzi F, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.19507
   Web of Science ®Google Scholar
• Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575–577. doi:10.1080/14712598.2023.2224499
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Patruno C, Fabbrocini G, Potestio L, Genco L, Napolitano M. Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(7):e901–e903. doi:10.1111/jdv.19011
   PubMed Web of Science ®Google Scholar
• Tran V, Ross G. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis. Australas J Dermatol. 2023;64(4):e352–e356. doi:10.1111/ajd.14139
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study. Drugs R D. 2022;22(3):245–252. doi:10.1007/s40268-022-00396-1
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther. 2023;13(2):651–660. doi:10.1007/s13555-022-00882-z
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Sheka D, Rankin B, et al. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol. 2023;89(6):1308–1311. doi:10.1016/j.jaad.2023.08.059
   PubMed Web of Science ®Google Scholar
• Boesjes CM, Van der Gang LF, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and/or baricitinib: results from the BioDay registry. Acta Derm Venereol. 2023;103:adv00872. doi:10.2340/actadv.v103.5243
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi:10.1111/1346-8138.16549
   PubMed Web of Science ®Google Scholar
• Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Invest Dermatol. 2023;16:3201–3212. doi:10.2147/CCID.S439053
   PubMed Web of Science ®Google Scholar
• Napolitano M, Potestio L, Hansel K, et al. Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience. Clin Exp Dermatol. 2023;48(3):247–249. doi:10.1093/ced/llac078
   PubMed Web of Science ®Google Scholar
• Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, et al. Treatment of severe atopic dermatitis with upadacitinib in clinical practice: short-term efficacy and safety results. J Investig Allergol Clin Immunol. 2023;33(3):211–213. doi:10.18176/jiaci.0831
   PubMed Web of Science ®Google Scholar
• Vanlerberghe J, Dezoteux F, Martin C, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2023;88(4):900–904. doi:10.1016/j.jaad.2022.10.034
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89(3):478–485. doi:10.1016/j.jaad.2023.05.033
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. J DermatolTreat. 2023;34(1):2183729. doi:10.1080/09546634.2023.2183729
   Google Scholar
• Merola JF, Butler DC, Mark T, Schneider S, Kim Y, Abuabara K. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis. JAMA Dermatol. 2023;159(10):1119–1123. doi:10.1001/jamadermatol.2023.2626
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J DermatolTreat. 2023;34(1):2216815. doi:10.1080/09546634.2023.2216815
   Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• Piscazzi F, Gargiulo L, Ibba L, et al. Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J DermatolTreat. 2023;34(1):2245510. doi:10.1080/09546634.2023.2245510
   Google Scholar
• Gargiulo L, Ibba L, Piscazzi F, et al. Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: a 16-week multicentre retrospective study. J Eur Acad Dermatol Venereol. 2024;2024:1. doi:10.1111/jdv.19862
   Google Scholar